Conbercept

康柏西普

Report date: 2025/10/29 16:03:26

Base Information

Drug NameConbercept
Drug Alias NameConberceptumRecombinant human VEGF receptor-Fc fusion protein朗沐LangmuLumitin +[8] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsDiabetic macular oedemaDiabetes MellitusUveitis +[12] 
Global Approved IndicationsMacular Degeneration
Approved Indications in ChinaMacular Degeneration
Original Approved Country/TerritoryMainland China
Original Approved Date2013/11/27
Country/TerritoryCzechiaBelgiumBulgaria +[33] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesChengdu Kanghong Biotechnologies Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesChengdu Kanghong Biotechnologies Co Ltd
Inactive CompaniesChongqing Medical UniversitySun Yat-Sen University
Active IndicationsDiabetic macular oedemaRetinal Vein OcclusionWet age-related macular degeneration +[5] 
Inactive IndicationsDiabetes MellitusUveitisChoroidal Neovascularization +[7] 

Other Information

ATC CodeS01LA
Related LinksN/A